In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on ZyVersa Therapeutics (ZVSA – Research Report), with a price target of $24.00.
Ed Arce has given his Buy rating due to a combination of factors surrounding ZyVersa Therapeutics’ potential in addressing systemic inflammation linked to obesity through their monoclonal antibody IC 100. Arce’s assessment is bolstered by research suggesting that IC 100 could be a key player in mitigating inflammation associated with various obesity-related conditions. This optimism is grounded in the evidence from numerous studies pointing to the activation of inflammasomes being a significant contributor to metabolic syndromes and the promotion of a tumorigenic environment in obesity-associated cancers. The anticipation of an Investigational New Drug (IND) filing for IC 100 in 2024 further supports the positive outlook, marking a major milestone for the program.
Additionally, Arce’s confidence is backed by the near-term initiation of a Phase 2a trial of another ZyVersa candidate, VAR 200, in patients with diabetic kidney disease, which represents a significant step forward for the company. The scientific foundation of the rating is also rooted in the understanding of the role of white adipose tissue in obesity and its complications such as insulin resistance, with insights into the NF-κB signaling pathway’s involvement in inflammation and metabolic processes. This comprehensive view of the biological underpinnings of ZyVersa’s therapeutic approach, along with the associated clinical development milestones, shapes Arce’s Buy rating for the company’s stock.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
ZyVersa Therapeutics (ZVSA) Company Description:
Larkspur Health Acquisition Corp is a blank check company.
Read More on ZVSA:
- ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
- ZyVersa data adds evidence of NLRP3 focus in obesity, says Piper Sandler
- ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
- ZyVersa publishes white paper detailing tole of inflammasomes, ASC specks
- ZyVersa Therapeutics highlights publication on inflammasome activation
